Chromodomain Helicase DNA Binding Protein as a Drug Target and Biomarker

Target Name: Chromodomain Helicase DNA Binding Protein

NCBI ID: P48788

Chromodomain Helicase DNA Binding Protein

Other Name(s): ATP-dependent helicase | Zinc finger helicase | CHD

Chromodomain Helicase DNA Binding Protein as a Drug Target and Biomarker

Chromodomain-containing proteins (CCPs) are a family of proteins that play a crucial role in various cellular processes. One of the subfamilies of CCPs is the Chromodomain Helicase DNA Binding Protein (nonspecified subtype), which is a protein that binds to DNA using its chromodomain. CCPs have been implicated in various diseases, including cancer, neurodegenerative diseases, and genetic disorders. The nonspecified subtype of Chromodomain Helicase DNA Binding Protein is an attractive drug target and biomarker due to its unique mechanism of action and its potential to modulate cellular processes.

Drug Target Potential

The nonspecified subtype of Chromodomain Helicase DNA Binding Protein is a potential drug target due to its unique mechanism of action. The protein functions as an ATP-dependent helicase, which means that it requires ATP to unwind and bind to DNA. This property makes it an attractive target for small molecules that can inhibit the protein's ATP-dependent binding to DNA. Additionally, the protein's role in regulating DNA replication and repair makes it an attractive target for drugs that aim to inhibit the damage caused by DNA replication errors, such as those associated with cancer.

Biomarker Potential

The nonspecified subtype of Chromodomain Helicase DNA Binding Protein has the potential to serve as a biomarker for various diseases. One of the main applications of the protein is its role in the regulation of DNA replication and repair. In cancer, the protein's dysfunction or aberrant expression can lead to DNA replication errors, which can contribute to tumor growth and the development of cancer. Therefore, the nonspecified subtype of Chromodomain Helicase DNA Binding Protein can be used as a biomarker for cancer, particularly in the Early Detection and Prognosis of Cancer (EDC) stage.

Another application of the protein is its role in neurodegenerative diseases. The protein has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The dysfunction of the protein can lead to the misfolding and aggregation of its protein, which can contribute to the development and progression of neurodegenerative diseases. Therefore, the nonspecified subtype of Chromodomain Helicase DNA Binding Protein can be used as a biomarker for neurodegenerative diseases.

In conclusion, the nonspecified subtype of Chromodomain Helicase DNA Binding Protein is an attractive drug target and biomarker due to its unique mechanism of action and its potential to modulate cellular processes. The protein's ability to bind to DNA using its chromodomain makes it an attractive target for small molecules that can inhibit the protein's function. Additionally, the protein's role in regulating DNA replication and repair makes it an attractive target for drugs that aim to inhibit the damage caused by DNA replication errors. The nonspecified subtype of Chromodomain Helicase DNA Binding Protein has the potential to serve as a valuable tool in the development of new treatments for various diseases.

Protein Name: Chromodomain Helicase DNA Binding Protein (nonspecified Subtype)

The "Chromodomain Helicase DNA Binding Protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Chromodomain Helicase DNA Binding Protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets